Product Description
Mechanisms of Action: EGFR Inhibitor,ERBB2 Inhibitor,VEGFR Inhibitor,TK Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Sanofi
Company Location: PARIS I0 75008
Company CEO: Paul Hudson
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: United States
Active Clinical Trial Count: 1
Highest Development Phases
Phase 2: Arthrogryposis|Kidney Diseases, Cystic|Polycystic Kidney Diseases|Polycystic Kidney, Autosomal Dominant
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| ACT17675 | P2 |
Completed |
Polycystic Kidney Diseases|Polycystic Kidney, Autosomal Dominant|Arthrogryposis|Kidney Diseases, Cystic |
2022-01-25 |